पृष्ठभूमि

Administering vaccines during a pregnancy है an important way to provide much needed protection at a time when a person is more vulnerable to गंभीर disease and complications. Vaccination during pregnancy also haएस the added benefit of allowing the transfer of maternal antibodies across the placenta to the unborn baby which will provide short-term protection (passive immunity) in the first few months of life.

During pregnancy, many anatomical and physical changes occur to support the growth of baby. Some of these changes include एक increase in blood volume, increased demand on the heart and lungs, increased physical pressure placed on अन्य organs due to an enlarged uterus, and changes को the immune system to ensure that the developing baby is not recognised as “foreign”. With these changes comes an increaseडी risk का experiencing severe symptoms and complications if exposed to infections, in particular respiratory infections.

The administration of

during pregnancy was historically avoided. However, as technologies have advanced, the benefits that some vaccines can offer when admमैंnistered during pregnancy now far outweigh any theoretical concerns for safety. This has been parटीicularly evident during pandemics such as H1N1 और COVID-19 where pregnant people were more likely to experience severe disease, hospitalisation and intensive care, affecting maternal and infant outcomes.

Recommendations

A thorough assessment of a person’s immunisation history and administration of any outstanding vaccines prior to pregnancy is an important part of preconception care. Administration of liv

ttenuated vaccines (e.g. MMR/वी) during pregnancy is contraindicated due to the theoretical risks associated with vaccine-related disease and its impact on a developing infant (see ‘Contraindicated vaccines’ below for more information). Live
attenuated vaccines should be given a minimum of 28 days prior to conception, या must be withheld until after delivery.

During pregnancy, there are multiple inactivated vaccines recommended and funded on the राष्ट्रीय टीकाकरण कार्यक्रम (NIP). Other inactivated vaccines can be administered in special circumstances (e.g. medical risk factors, travel) but are not routinely recommended. Refer to the Australian Immunisation Handbook: Vaccines that are not routinely recommended in pregnancy अधिक जानकारी के लिए।

Correctly timing the administration of vaccines during a pregnancy is important and varies with each vaccine. Guidance on timing is based on whether the resulting immune response is intended to protect the mother, the infant, or both.

इन्फ्लुएंजा

इन्फ्लुएंजा vaccination during pregnancy is safe and strongly recommended to protect the mother from infection and avoid complications of disease. During pregnancy there is an increased effort required by the lungs. Influenza viruses affect lung tissue meaning infection adds further strain. As a result, pregnant people with influenza infection have a higher likelihood of requiring hospitalisation and intensive care than non

pregnant people with influenza infection. Influenza infections during pregnancy also increase the risk of preterm birth, babies being born at low birthweight and stillbirths. 

Antibodies derived from maternal vaccination can also cross the placenta providing some protection to the infant. It is estimated that vaccination during pregnancy can reduce the risk of influenza infection by half in infants less than 6 months of age. This is important because influenza vaccines cannot be administered to infants until they are 6 months of age. 

Influenza vaccines are recommended annually and can be given at any time during a pregnancy. If a person is vaccinated before becoming pregnant, they should receive another dose when they are pregnant (minimum 4 weeks between doses). When a pregnancy crosses over influenza seasons, pregnant people are recommended to receive two vaccines, one for each season.  

को देखें एमवीईसी: इन्फ्लुएंजा for up

को
date information on current influenza vaccines.

काली खांसी

काली खांसी vaccination during pregnancy is safe and effective and is recommended to protect both the pregnant person and, most importantly, the infant.

Infants under 6 months of age infected with pertussis have the highest rates of hospitalisation and death compared with people infected in other age groups. Symptoms include periods of intense coughing (paroxysmal coughing) with apnoea where infants stop breathing for a short period. There can be vomiting and difficulty feeding due to prolonged paroxysmal coughing episodes. Complications of pertussis in infants include pneumonia (lung infection), seizures and encephalitis (brain inflammation) which can be fatal. 

Infants require a 3

dose course of pertussis vaccines (doses given at 6 weeks, 4 months and 6 months) to be considered fully protected. Vaccination during pregnancy can reduce the likelihood of infections occurring in infants who are too young to have completed this course by 90%. 

A single dose of vaccine (which is provided in combination with डिप्थीरिया और धनुस्तंभ) should be administered between 20 and 32 weeks of gestation, in every pregnancy (including pregnancies that are closely spaced). If the pregnant person was vaccinated prior to pregnancy, they should still receive another vaccine within the pregnancy to ensure the infant will be passively protected. If an infant is born within 2 weeks of their mother’s vaccine, the passive immunity passed onto the infant may be suboptimal. 

को देखें एमवीईसी: Pertussis अधिक जानकारी के लिए।

रेस्पिरेटरी सिंकाइटियल वायरस (आरएसवी)

Vaccination against RSV during pregnancy is recommended to provide passive immunity to infants. From 2025, vaccination during pregnancy will be funded on the NIP. 

Current data shows that almost all children will be infected with RSV by the time they turn 2 years old. Whilst most infections are mild, bronchiolitis (inflammation of the small airways) and pneumonia (lung infection) can occur and may lead to hospitalisation for supportive measures such as oxygen therapy and rehydration. Infants with specified risk factors such as preterm birth, cardiac conditions and chronic lung disease are more likely to experience severe disease. Clinical trials demonstrate that when vaccines are administered during pregnancy the risks of hospitalisation due to severe RSV infection is reduced by 57% in infants less than 6 months of age.  

A single dose of Abrysvo should be administered between 28 and 36 weeks’ gestation (NB: Arexvy is नहीं registered for use in pregnancy). There is currently no recommendation for further doses in subsequent pregnancies; however, this may change as more data becomes available. When a pregnant person is vaccinated within 2 weeks of delivery, infant protection is likely to be reduced (many jurisdictions are funding infant RSV prevention programs for infants with medical risk factors and those with suboptimal passive protection). 

अधिक जानकारी के लिए देखें MVEC: RSV.

प्रतिबंधित टीके

The RSV vaccine Arexvy must नहीं be administered to pregnant women due to a lack of safety and efficacy data. Should inadvertent administration occur, it should be reported to the adverse event reporting service in your jurisdiction and the patient should be informed using the open disclosure process.

सभी जीवित-क्षीण टीके हैं contraindicated during pregnancy due to the potential risk to the unborn baby. In most circumstances the risk is hypothetical; however, there is insufficient evidence to support vaccination in this patient group.

If a live

attenuated vaccine is inadvertently administered को a pregnant person, the person should be informed of the administration error and reassured using the open disclosure framework. The limited safety data from inadvertent administration of MMR and varicella vaccines is reassuring. The administration error should be reported to tवह adverse event reporting service in your jurisdiction.

Table 1: Live

attenuated vaccines contraindicated in pregnancy

WordPress Tables Plugin

* oral vaccine
^ P
regnant people should be advised not to go to पीला बुखार endemic areas. However, if travel cannot be avoided a specialist consultation is advised.

Access

All vaccines recommended during pregnancy are funded on the NIP.

These vaccines are available via GP services, परिषदों, hospital immunisation services, some pharmacies and other health services.

आमतौर पर पूछे जाने वाले प्रश्न

  • Should pregnant people receive COVID‑19 vaccines?

    If a pregnant person has not previously received a primary course of COVID-19 vaccination, they should be receive a single dose of mRNA COVID

    19 vaccine during pregnancy. This can be administered at any stage during pregnancy. If a pregnant person has additional risk factors for severe disease they may be recommended further doses on a case
    by
    case basis.

    Unvaccinated pregnant people have an increased risk of experiencing severe disease, requiring intensive care support if infected with COVID

    19. Infections during pregnancy also increase the likelihood of preterm birth and stillbirth.

    Real world surveillance of local and international data on mRNA COVID

    19 vaccine administration in pregnant people has shown no significant safety concerns for either the mother or the baby. Further to this, antibodies have been detected in the cord blood and breastmilk of vaccinated people, suggesting a transfer of protection to the baby.

  • Can vaccines recommended in pregnancy be co-administered (given on the same day)?

    Yes. If indicated, all the recommended vaccines in pregnancy can safely be given on the same day. It is important to refer to the recommended timing of administration for each vaccine to ensure optimal protection.

  • Can side effects of vaccination be harmful for a developing infant if a vaccine is administered during pregnancy?

    Clinical trials have demonstrated that the vaccines recommended during pregnancy have a good safety profile and are not associated with adverse outcomes for the infant.

    Live

    attenuated vaccines are contraindicated in pregnancy due to a theoretical risk of vaccine
    related disease.

लेखक: मिशेल जाइल्स (संक्रामक रोग सलाहकार, मोनाश स्वास्थ्य) और राचेल मैकगायर (एमवीईसी शिक्षा नर्स समन्वयक)

द्वारा समीक्षित: Rachael McGuire (MVEC Education Nurse Coordinator) and Katie Butler (MVEC Education Nurse)

तारीख: November 2024

नई जानकारी और टीके उपलब्ध होते ही इस अनुभाग की सामग्रियों को अद्यतन किया जाता है। मेलबर्न वैक्सीन एजुकेशन सेंटर (MVEC) कर्मचारी सटीकता के लिए नियमित रूप से सामग्रियों की समीक्षा करते हैं।

You should not consider the information on this site to be specific, professional medical advice for your personal health or for your family’s personal health. For medical concerns, including decisions about vaccinations, medications and other treatments, you should always consult a healthcare professional.

MVEC acknowledges the traditional owners of the lands on which we live, work and educate. We pay our respects to their Elders, past, present and emerging.
We are committed to honouring Australian Aboriginal and Torres Strait Islander peoples’ unique cultural and spiritual relationships to the land, waters and seas.

एमवीईसी के बारे में

मेलबोर्न वैक्सीन एजुकेशन सेंटर (एमवीईसी) एक शैक्षिक वेबसाइट है, जिसे स्वास्थ्य सेवा पेशेवरों और जनता के सदस्यों दोनों के लिए अद्यतित टीकाकरण जानकारी प्रदान करने के उद्देश्य से विकसित किया गया है। हम मर्डोक चिल्ड्रन्स रिसर्च इंस्टीट्यूट (MCRI), एक शोध संगठन पर आधारित हैं, और SAEFVIC (समुदाय में टीकाकरण के बाद प्रतिकूल घटनाओं की निगरानी), विक्टोरियन वैक्सीन सुरक्षा सेवा से संबद्ध हैं।

इसे साझा करें